Canaccord Genuity Group Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $429.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price increased by Canaccord Genuity Group from $415.00 to $429.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group’s price target points to a potential upside of 28.95% from the company’s current price.

Several other research firms have also recently issued reports on ALNY. Oppenheimer started coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price objective on the stock. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, January 15th. Piper Sandler reaffirmed an “overweight” rating and set a $489.00 price objective (up previously from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, October 31st. Chardan Capital decreased their target price on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Finally, Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Twenty-two analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $477.96.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $332.68 on Tuesday. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $495.55. The firm has a market cap of $44.12 billion, a price-to-earnings ratio of 194.55 and a beta of 0.35. The company’s 50-day moving average is $369.58 and its two-hundred day moving average is $423.61. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter last year, the firm earned ($0.65) earnings per share. The business’s quarterly revenue was up 84.9% compared to the same quarter last year. Research analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the business’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total transaction of $848,055.70. Following the transaction, the executive vice president owned 21,264 shares in the company, valued at $7,874,697.12. The trade was a 9.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $1,008,778.60. Following the sale, the executive vice president owned 57,465 shares in the company, valued at approximately $20,852,324.55. The trade was a 4.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 36,578 shares of company stock valued at $12,416,105 over the last ninety days. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Root Financial Partners LLC acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth about $25,000. Salomon & Ludwin LLC bought a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $27,000. HM Payson & Co. acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $27,000. Golden State Wealth Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” on ALNY and set a $510 price target, implying substantial upside vs. current levels — a strong analyst vote of confidence for growth expectations. Read More.
• Positive Sentiment: Canaccord Genuity raised its price target from $415 to $429 and kept a “buy” rating, supporting near‑term buyer interest. Read More.
• Positive Sentiment: Freedom Capital Markets upgraded ALNY (reported via MSN), and a Motley Fool piece highlighted an influential pundit upgrade that helped lift momentum earlier in the week — both items can attract more buying. Read More. · Read More.
• Neutral Sentiment: Valuation commentary: a Yahoo Finance piece framed Alnylam’s valuation as mixed — models show bullish fair‑value scenarios but recent returns are uneven; useful context for longer‑term investors rather than an immediate catalyst. Read More.
• Neutral Sentiment: Reported short‑interest figures in the feed show zero/NaN values and a 0.0 days‑to‑cover metric — this appears to be a data/reporting artifact and should be treated as non‑actionable until exchange‑confirmed. (No reliable link available.)
• Negative Sentiment: Multiple insider sales were disclosed this week that could pressure sentiment: CEO Yvonne Greenstreet sold 6,958 shares (~$310 avg) and several EVPs (including Kevin Fitzgerald, Jeffrey Poulton, Tolga Tanguler, Pushkal Garg) sold shares in mid‑thousands at ~$310–332 — large insider liquidity events can be perceived negatively by investors. Read More. · Read More.
• Negative Sentiment: Some sell‑side pressure: Chardan trimmed a price target to $425 and other brokers (e.g., Morgan Stanley, Wells Fargo) have lowered targets or applied neutral/equal‑weight ratings earlier — mixed analyst views add volatility risk vs. unanimous buy signals. Read More.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.